Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10142189 | 0.85 | ACACB (0.39) | ACACBHDAC3HDAC1HDAC2PIK3CD | |
| SCHEMBL15998174 | 0.85 | ACACB (0.39) | ACACBHDAC3HDAC1HDAC2PIK3CD | |
| SCHEMBL13057636 | 0.83 | LMNA (0.46) | PSMB5 | |
| SCHEMBL13811588 | 0.82 | ACACB (0.40) | ACACBHDAC3HDAC1HDAC2PIK3CD | |
| SCHEMBL19088597 | 0.81 | ACACB (0.37) | ACACBHDAC3HDAC1HDAC2PIK3CD | |
| SCHEMBL25885731 | 0.79 | ACACB (0.39) | ACACBHDAC3HDAC1HDAC2PIK3CD | |
| SCHEMBL10186030 | 0.79 | ACACB (0.39) | ACACBHDAC3HDAC1HDAC2PIK3CD | |
| SCHEMBL4765091 | 0.79 | CARM1 (0.39) | HDAC3HDAC1HDAC2 | |
| SCHEMBL12184829 | 0.77 | HDAC3 (0.43) | ACACBHDAC3HDAC1HDAC2CNR2 | |
| SCHEMBL22644001 | 0.77 | ACACB (0.35) | ACACBHDAC3HDAC1HDAC2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293569-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-09-21 | — | — | US | disclosed |
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20190350960-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-11-21 | — | — | US | disclosed |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2018-05-31 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9919003-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2018-03-20 | — | — | US | disclosed |
| US-9855289-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170290850-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INTERNATIONAL BIOTECH, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012941-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7973013-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2010093608-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | ACACB 623/4885HDAC3 192/4885HDAC1 420/4885 |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, NSUN2 | ACACB 4481/4885HDAC3 655/4885HDAC1 498/4885 |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, CDA | ACACB 3322/4885HDAC3 615/4885HDAC1 1381/4885 |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | ACACB 4144/4885HDAC3 627/4885HDAC1 1858/4885 |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, RNGTT, SLC29A1 | ACACB 3843/4885HDAC3 896/4885HDAC1 1431/4885 |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | ACACB 623/4885HDAC3 192/4885HDAC1 420/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | ACACB 4365/4885HDAC3 1406/4885HDAC1 1202/4885 |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | ACACB 3979/4885HDAC3 422/4885HDAC1 576/4885 |
| US-20230293569-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | NAMPT, NUDT15, NME4 | ACACB 2214/4885HDAC3 790/4885HDAC1 685/4885 |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | CDA, PNP, MTAP | ACACB 3669/4885HDAC3 448/4885HDAC1 920/4885 |
| US-20170290850-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | ACACB 623/4885HDAC3 192/4885HDAC1 420/4885 |
| US-20190350960-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | NAMPT, NME4, NUDT15 | ACACB 2059/4885HDAC3 724/4885HDAC1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.